These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23652475)

  • 41. Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):140-1. PubMed ID: 26445204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting the Overuse of PCSK-9 Inhibitors.
    Rodriguez-Gutierrez R; Shah ND; Montori VM
    JAMA; 2015 Nov; 314(18):1909-10. PubMed ID: 26547456
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A keen eye for risk.
    Ford TJ; Rocchiccioli P
    BMJ; 2018 Feb; 360():j5884. PubMed ID: 29419393
    [No Abstract]   [Full Text] [Related]  

  • 49. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.
    Stein EA; Raal FJ
    Curr Cardiol Rep; 2015 Nov; 17(11):104. PubMed ID: 26385394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trial watch: PCSK9 antibody reduces LDL cholesterol.
    Crunkhorn S
    Nat Rev Drug Discov; 2012 Jan; 11(1):11. PubMed ID: 22212668
    [No Abstract]   [Full Text] [Related]  

  • 51. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 53. PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al.
    Stein EA
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):427-431. PubMed ID: 27669716
    [No Abstract]   [Full Text] [Related]  

  • 54. Back to basics: PCSK9 as a new target for the LDL receptor.
    Corral P
    Arq Bras Cardiol; 2014 Jan; 102(1):e5-8. PubMed ID: 24652095
    [No Abstract]   [Full Text] [Related]  

  • 55. Genetics. Simple genetics for a complex disease.
    Cohen JC; Hobbs HH
    Science; 2013 May; 340(6133):689-90. PubMed ID: 23661745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The promises of PCSK9 inhibition.
    Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G
    Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM; Stefanutti C; Sniderman A; Watts GF
    Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. One-shot, one cure with genome editing for dyslipidemia.
    Gupta RM
    Circ Cardiovasc Genet; 2014 Dec; 7(6):967-8. PubMed ID: 25516627
    [No Abstract]   [Full Text] [Related]  

  • 59. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.
    Lee P; Hegele RA
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1411-23. PubMed ID: 23889692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biomedicine. Lowering LDL--not only how low, but how long?
    Brown MS; Goldstein JL
    Science; 2006 Mar; 311(5768):1721-3. PubMed ID: 16556829
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.